MADRID, April 22, 2025 /PRNewswire/ -- Suanfarma, a global company specializing in the development, production, and commercialization of active pharmaceutical ingredients (APIs) and high-value CDMO ...

The "Enterprise Tech Ecosystem Series: Boehringer Ingelheim 2025" company profile has been added to ResearchAndMarkets.com's offering. Boehringer Ingelheim International: Leading the Way in ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...

Clarivate Plc , a leading global provider of transformative intelligence, today announced the launch of DRG Commercial Analytics 360?a solution designed to empower medtech companies with advanced ...

Suanfarma, a global company specializing in the development, production, and commercialization of active pharmaceutical ...

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

With a career spanning more than 30 years, Pere has held technical and strategic executive positions at leading pharmaceutical companies such as Uquifa, Boehringer Ingelheim, and Esteve Química ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...